Search filters

List of works by D Ross Camidge

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer ⬇️

scientific article published on February 1, 2012

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib

scientific article

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

scientific article

A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer

scientific article

A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.

scientific article

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer

scientific article

A time to test, a time to treat ⬇️

scientific article published on April 1, 2012

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

scientific article

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

scientific article published on 04 September 2012

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

scientific article

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

scientific article

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer

scientific article published on 8 April 2016

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed ⬇️

scientific article published on April 1, 2011

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

scientific article

Buyer beware: understanding the assumptions behind health economic assessments in personalized cancer care

scientific article

Ceritinib in ALK-rearranged non-small-cell lung cancer

scientific article

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

scientific article

Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.

scientific article published on September 2013

Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer ⬇️

scientific article published on August 6, 2013

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

scientific article published on 26 January 2015

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

scientific article published in January 2018

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

scientific article

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancer ⬇️

scientific article published on January 26, 2012

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

scientific article

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

scientific article

Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer ⬇️

scientific article published on December 20, 2012

Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience

scientific article published on 9 September 2016

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

scientific article

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

scientific article

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

scientific article

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer

scientific article

Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-Mutated Papillary Renal Cell Carcinoma ⬇️

scientific article published on April 22, 2013

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer ⬇️

scientific article published on December 1, 2012

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

scientific article published on 24 October 2016

Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status

scientific article published on 26 March 2016

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study

scientific article

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

scientific article

Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy

scientific article published on 10 September 2013

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer

scientific article published on 25 January 2010

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer ⬇️

scientific article published on January 26, 2012

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

scientific article

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

scientific article

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors

scientific article

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

scientific article

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

scientific article

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer

scientific article

Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers

scientific article

Prognosis without treatment as a modifier in health economic assessments

scientific article

Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer

scientific article published on December 2010

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

scientific article

Response assessment criteria for brain metastases: proposal from the RANO group.

scientific article

Rociletinib in EGFR-mutated non-small-cell lung cancer

scientific article

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib

scientific article

Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer

scientific article

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study

scientific article

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

scientific article

Targeting ALK, ROS1, and BRAF Kinases ⬇️

scientific article published on December 1, 2012

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

scientific article

The intersection between cannabis and cancer in the United States ⬇️

scientific article published on October 21, 2011

Treating ALK-positive lung cancer—early successes and future challenges ⬇️

scientific article published on 03 April 2012

Updates in the management of brain metastases.

scientific article

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

scientific article

hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing ⬇️

scientific article published on October 25, 2010

Paulina is supported by:

About Paulina

Help